Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Patients with pulmonary hypertension due to interstitial lung disease were randomly assigned to inhaled treprostinil or placebo. At 16 weeks, there was a significant improvement in exercise capacity with inhaled treprostinil as compared with placebo as assessed by a 6-minute walk test.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-01, Vol.384 (4), p.325-334
Hauptverfasser: Waxman, Aaron, Restrepo-Jaramillo, Ricardo, Thenappan, Thenappan, Ravichandran, Ashwin, Engel, Peter, Bajwa, Abubakr, Allen, Roblee, Feldman, Jeremy, Argula, Rahul, Smith, Peter, Rollins, Kristan, Deng, Chunqin, Peterson, Leigh, Bell, Heidi, Tapson, Victor, Nathan, Steven D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with pulmonary hypertension due to interstitial lung disease were randomly assigned to inhaled treprostinil or placebo. At 16 weeks, there was a significant improvement in exercise capacity with inhaled treprostinil as compared with placebo as assessed by a 6-minute walk test.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2008470